Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer.
Rocío Díaz AcedoMercedes Galvan BanqueriSilvia Artacho CriadoEva María Fernández ParraRocío Jiménez GalánAna Isabel Gago SánchezJuan Francisco Marín PozoMaría José Martínez BautistaPublished in: International journal of clinical pharmacy (2023)
In a real-world population with previously treated mUBC, atezolizumab seems to provide clinically relevant benefit, which is even higher for patients with ECOG 0-1 and without liver metastases, with an acceptable safety profile.